Prothena Corporate Overview November 5, 2019 Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things: the strength of our capital position; the potential of our pipeline and the potential to accelerate it and reach significant value inflection points; the design, proposed mechanism of action and possible clinical benefits of prasinezumab (PRX002/RG7935), and its potential as a treatment for Parkinson's disease; the design of the Phase 2 PA ...

Prothena Corporate Overview August 6, 2019 Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things: the strength of our capital position; the potential of our pipeline and the potential to accelerate it and reach significant value inflection points; the design, proposed mechanism of action and possible clinical benefits of prasinezumab (PRX002/RG7935), and its potential as a treatment for Parkinson's disease; the design of the Phase 2 PASA ...

Prothena Corporate Overview May 7, 2019 Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things: the strength of our capital position; the potential of our pipeline and the potential to accelerate it and reach significant value inflection points; the design, proposed mechanism of action and possible clinical benefits of prasinezumab (PRX002/RG7935), and its potential as a treatment for Parkinson's disease; the design of the Phase 2 PASADEN ...

Prothena Corporate Overview March 20, 2019 Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things: the strength of our capital position; the potential of our pipeline and the potential to accelerate it and reach significant value inflection points; the design, proposed mechanism of action and possible clinical benefits of prasinezumab (PRX002/RG7935); the design of the Phase 2 PASADENA study of prasinezumab; amounts we might receive under ...

Prothena Corporation PLC (NASDAQ:PRTA) Q4 2018 Earnings Conference Call February 14, 2019 4:30 PM ET Company Participants Ellen Rose - Head, Communications Gene Kinney - President, CEO & Director Radhika Tripuraneni - Chief Development Officer Wagner Zago - Chief Scientific Officer Tran Nguyen - CFO & COO Conference Call Participants Christopher Marai - Nomura Securities Kennen MacKay - RBC Capital Markets Robert Hazlett - BTIG Operator Good day, ladies and gentlemen, and welcome to the Prothena Fourth Quar ...